Increasing Cases of Dermatophyte Infections to Fuel Demand for Dermatophytosis Treatment

With the increasing prevalence of various types of fungal infections, the market for dermatophytosis treatment is observing a strong growth across the world. Dermatophytosis is caused by a fungus, called dermatophytes, which belongs to a family of organisms that can easily break down the keratin in nails, epidermis, hooves and horns, and epidermis. Dermatophytosis generally develops through direct contact with infected wounds and infected shoes, towels, or shower stalls. Drug makers are actively working on developing a highly efficient treatment for this fungus infection.

In this blog post, researchers at TMR Research are answering some of the important queries regarding the global dermatophytosis treatment market:

What are the key factors that are influencing the global market for dermatophytosis treatment?

The increasing population base of individuals with weak immune systems is the main factor behind the growth of the global dermatophytosis treatment market. Since the immune system weakens with age, the constantly increasing geriatric population has surfaced as the key contributor to this market. Apart from this, the rising sedentary lifestyle and the augmenting prevalence of hospital-acquired infections (HAIs) are also resulting in a higher rate of dermatophytosis, driving the demand for dermatophytosis treatment.

On the flip side, the dearth of awareness regarding dermatophytosis and several related diseases and their treatment options may limit the growth prospects of this market in the near future. The reluctance among patients in going for the treatment of dermatophytosis may also hamper the growth of this market, worldwide, over the next few years.

Get Sample Copy of this Report @

Which of the regional markets is likely to dominate the worldwide dermatophytosis treatment market?

Presently, North America is dominating the global market for dermatophytosis treatment, with Europe trailing closely. Availability of favorable reimbursement coverage, presence of immensely developed healthcare infrastructure, greater healthcare spending, higher awareness among people regarding dermatophytosis and the benefits of early diagnosis and treatment, and the ample availability of advanced healthcare facilities are the main factors that has been supporting the markets for dermatophytosis treatment in North America and Europe. Both the regional markets are likely to remain on the top over the next few years.

Which are the most popular strategies that players are adopting in the global market?

Novartis, Quinnova Pharmaceuticals, Tinea Pharmaceuticals, Sun Pharmaceuticals, NB Therapeutics, Valeant Pharmaceuticals, AmDerma Pharmaceuticals, Merz Pharma, and Perrigo are some of the leading players in the global market for dermatophytosis treatment. These players are aggressively focused towards offering advanced and highly effective treatment options for dermatophytosis. They are likely to get increasingly involved into strategic collaborations, specifically mergers and acquisitions to strengthen their position in this market.

Shift towards Sedentary Lifestyles to Fuel Demand for Dermatophytosis Treatment

San Francisco, California, July 06, 2017: A market intelligence report by TMR Research, titled “Dermatophytosis Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” offers a detailed evaluation of the trends and opportunities in the market. The report serves with a 360-degree view of the global dermatophytosis treatment market by providing insights into all important aspects, including diagnosis type, drug type, regional segmentation, and vendor landscape.

The widening pool of patients with weak immune systems is one of the primary factors augmenting the need for dermatophytosis treatment. The rapidly growing global population of geriatrics is also stoking the growth of the market, since immune system weakens with aging. Moreover, changing lifestyles play a pivotal role in the development of the dermatophytosis treatment market. People are shifting to sedentary routines, which include minimum physical activities, thereby hampering their immune systems. The increasing incidence of hospital-acquired diseases are resulting in higher rate of dermatophytosis, thereby providing a fillip to the market.

On the other hand, the lack of awareness about dermatophytosis results in a large section of patient pool remaining undiagnosed and untreated. This, in turn, limits the market from realizing its utmost potential. Additionally, reluctance on patients’ part in receiving dermatophytosis treatment is impeding the upward rise of the global market.

Geographically, North America and Europe will account for a large cumulative share in the global arena. The growth of these regions can be attributed to favorable reimbursement framework, the presence of advanced healthcare infrastructure, and rising healthcare spending. The increasing awareness among the populace regarding the merits of early diagnosis and treatment of dermatophytosis is also one of the primary factors contributing to the growth of the regions.

Asia Pacific offers immense growth opportunities to the global dermatophytosis treatment market. Developing healthcare infrastructure owing to the increasing efforts by governments is providing a significant push to the market in the region. China and India are poised to be sights of high growth rates during the forecast period, due to the rising awareness regarding dermatophytosis treatment among the populace. In Latin America, Argentina and Brazil will be the primary revenue contributors to the market.

The majority of key players in the global dermatophytosis treatment market are entering into collaborations with research institutes and universities for conducting clinical trials to develop effective treatment methods. Some of the prominent participants in the market are Novartis AG, Sun Pharmaceutical Industries Limited, Quinnova Pharmaceuticals Inc., NB Therapeutics Inc., Tinea Pharmaceuticals, Valeant Pharmaceuticals International Inc., AmDerma Pharmaceuticals LLC, Perrigo Company plc., and Merz Pharma GmbH & Co. KgaA.